Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OPY
OPY logo

OPY Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
91.280
Open
88.500
VWAP
90.05
Vol
31.93K
Mkt Cap
973.82M
Low
87.925
Amount
2.88M
EV/EBITDA(TTM)
7.11
Total Shares
10.71M
EV
2.20B
EV/OCF(TTM)
11.65
P/S(TTM)
0.64
Oppenheimer Holdings Inc., through its subsidiaries, is a middle market investment bank and full-service broker-dealer. The Company is engaged in a broad range of activities in the financial services industry, including retail securities brokerage, institutional sales and trading, investment banking (corporate and public finance), equity and fixed income research, market-making, trust services, and investment advisory and asset management services. The Company’s Wealth Management segment provides a comprehensive array of financial services through a network of financial advisors. Its wealth management services include full-service brokerage, wealth planning, and margin lending. Its Capital Markets segment includes investment banking, institutional equities sales, trading, and research, taxable fixed income sales, trading, and research, public finance and municipal trading, as well as the Company's operations in the United Kingdom, Hong Kong and Israel.
Show More

Events Timeline

(ET)
2025-12-12
08:10:00
Oppenheimer Announces Special Cash Dividend of $1.00 per Share
select
2025-09-30 (ET)
2025-09-30
06:05:50
Oppenheimer Enhances Custody and Prime Services Offering
select
2025-01-31 (ET)
2025-01-31
07:04:32
Oppenheimer Holdings reports Q4 EPS 92c vs. 98c last year
select
2024-10-25 (ET)
2024-10-25
08:04:10
Oppenheimer Holdings reports Q3 basic EPS $2.38 vs. $1.32 last year
select
2024-09-03 (ET)
2024-09-03
06:06:14
Oppenheimer appoints Mark Hovanic as executive director, branch manager
select

News

NASDAQ.COM
8.5
04-01NASDAQ.COM
Centessa Pharmaceuticals Acquired by Eli Lilly for Up to $7.8 Billion
  • Acquisition Overview: Centessa Pharmaceuticals has entered into an acquisition agreement with Eli Lilly for up to $7.8 billion, with a cash purchase price of $38 per share representing a nearly 38% premium over Monday's closing price, indicating strong market confidence in its potential.
  • Drug Development Prospects: Centessa is developing a novel class of drugs, specifically orexin receptor 2 (OX2R) agonists targeting daytime sleepiness and other neurological conditions, with its most promising drug, cleminorexton, showing best-in-class potential in Phase 2 clinical trials, positioning it as a market leader.
  • Market Potential Analysis: According to Oppenheimer, Centessa's experimental therapies could capture a significant share of the $20 billion market for severe sleep disorder treatments, further enhancing Eli Lilly's strategic diversification of its development pipeline.
  • Regulatory and Shareholder Approval: The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval, and upon completion, Centessa's shareholders will receive a non-transferrable contingent value right valued at up to $9 per share.
Fool
8.5
04-01Fool
Centessa Pharmaceuticals Acquired by Eli Lilly for Up to $7.8 Billion
  • Acquisition Overview: Eli Lilly is acquiring Centessa Pharmaceuticals for up to $7.8 billion, offering $38 per share in cash, which represents a nearly 38% premium over Centessa's closing price on Monday, providing substantial returns for its investors.
  • Contingent Value Rights: Centessa shareholders will also receive a non-transferable contingent value right that could be worth up to $9 per share if certain regulatory milestones for its investigational drugs are met, enhancing the attractiveness and potential profitability of the deal.
  • Market Potential Analysis: Centessa is developing a novel class of drugs targeting daytime sleepiness and other neurological conditions, with its leading experimental drug, cleminorexton, showing best-in-class potential in Phase 2 clinical studies, which could position it well in a $20 billion market for severe sleep disorder treatments.
  • Strategic Investment Intent: Eli Lilly is leveraging the profits from its successful GLP-1 drugs, Mounjaro and Zepbound, to diversify its development pipeline, with Centessa's experimental therapies poised to become blockbuster sellers, further solidifying Lilly's leadership in the neuroscience sector.
CNBC
6.0
03-30CNBC
Latest Wall Street Rating Updates
  • UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
  • HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
  • Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
  • Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
PRnewswire
5.0
03-24PRnewswire
Peter Bennett to Lead Corporate Executive Services Team
  • Leadership Changes: Oppenheimer has appointed Chris DeFalco and John Hyland as Co-Heads of the Equity Capital Markets Investment Banking group, aiming to drive continued growth by deepening product expertise and enhancing competitiveness in core industries.
  • Functional Integration: Peter Bennett will transition from Head of Equity Capital Markets to lead the Corporate Executive Services team, focusing on strengthening connectivity between Investment Banking and Wealth Management to provide a more coordinated client experience, reflecting the firm's commitment to evolving client needs.
  • Experienced Team: DeFalco, who joined in 2015, has completed over 285 equity and equity-linked offerings, while Hyland has played a crucial role in expanding IPOs since joining in 2021, leveraging their extensive capital markets experience to advance Oppenheimer's ECM platform.
  • Strengthening Client Relationships: The new leaders emphasize a focus on consistent execution and direct dialogue with clients, aiming to support corporate leaders not only at the transaction level but also as long-term partners as their priorities evolve.
Newsfilter
5.0
03-24Newsfilter
Peter Bennett to Lead Corporate Executive Services Team
  • Leadership Changes: Oppenheimer & Co. Inc. announced that Chris DeFalco and John Hyland have been appointed as Co-Heads of the Equity Capital Markets Investment Banking group, aiming to drive the firm's continued growth by deepening product expertise.
  • Strategic Integration: Peter Bennett will transition from Head of Equity Capital Markets to lead the Corporate Executive Services team, aiming to strengthen connectivity between Investment Banking and Wealth Management, thereby providing a more coordinated client experience.
  • Industry Expertise: Since joining in 2015, DeFalco has completed over 285 equity and equity-linked offerings as bookrunner or lead manager, showcasing his expertise in the consumer, healthcare, and technology sectors.
  • Capability Expansion: Hyland, who joined in 2021, has successfully driven Oppenheimer's IPO expansion across consumer, financial institutions, industrials, and technology, bringing over 20 years of capital markets experience and participating in over 200 equity offerings, further solidifying the firm's market position.
CNBC
4.5
03-23CNBC
Market Bounce Expected to be Short-Lived Amid Downside Risks
  • Market Bounce: Following President Trump's 'productive' talks with Iran, the S&P 500 surged 1.2% on Monday, with futures rallying as much as 4.1%, yet analysts caution that this rebound may be short-lived.
  • Technical Indicator Analysis: The S&P 500 has fallen below its 200-day moving average, with analysts suggesting that while a near-term bounce could push it back to 6,900, the longer-term trend indicates significant downside risks ahead.
  • Investor Sentiment: Analysts at BTIG argue that investors remain complacent, with the S&P 500 facing a potential drop to 6,000, representing a 7% decline from Friday's close, indicating ongoing market vulnerability.
  • Small-Cap Performance: The Russell 2000 index has entered correction territory with a drop exceeding 10%, while the Nasdaq Composite and Dow Jones Industrial Average also experienced intraday declines of over 10% on Friday, highlighting the fragility of the market.

Valuation Metrics

The current forward P/E ratio for Oppenheimer Holdings Inc (OPY.N) is 10.81, compared to its 5-year average forward P/E of 18.27. For a more detailed relative valuation and DCF analysis to assess Oppenheimer Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.27
Current PE
10.81
Overvalued PE
23.21
Undervalued PE
13.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.55
Current PS
0.00
Overvalued PS
0.68
Undervalued PS
0.42

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

profitable small caps under $1B market cap
Intellectia · 544 candidates
Market Cap: <= 1000.00MMarket Cap Category: small, micro, nanoNet Margin: >= 0.00Return On Equity: >= 0.0%
Ticker
Name
Market Cap$
top bottom
FMBH logo
FMBH
First Mid Bancshares Inc
999.42M
ODC logo
ODC
Oil-Dri Corporation of America
997.78M
UFCS logo
UFCS
United Fire Group Inc
996.64M
NBBK logo
NBBK
NB Bancorp Inc
984.61M
KBDC logo
KBDC
Kayne Anderson BDC Inc
982.84M
BHRB logo
BHRB
Burke & Herbert Financial Services Corp
981.29M

Whales Holding OPY

R
RBF Capital LLC
Holding
OPY
-12.24%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Oppenheimer Holdings Inc (OPY) stock price today?

The current price of OPY is 90.95 USD — it has increased 1.52

What is Oppenheimer Holdings Inc (OPY)'s business?

Oppenheimer Holdings Inc., through its subsidiaries, is a middle market investment bank and full-service broker-dealer. The Company is engaged in a broad range of activities in the financial services industry, including retail securities brokerage, institutional sales and trading, investment banking (corporate and public finance), equity and fixed income research, market-making, trust services, and investment advisory and asset management services. The Company’s Wealth Management segment provides a comprehensive array of financial services through a network of financial advisors. Its wealth management services include full-service brokerage, wealth planning, and margin lending. Its Capital Markets segment includes investment banking, institutional equities sales, trading, and research, taxable fixed income sales, trading, and research, public finance and municipal trading, as well as the Company's operations in the United Kingdom, Hong Kong and Israel.

What is the price predicton of OPY Stock?

Wall Street analysts forecast OPY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Oppenheimer Holdings Inc (OPY)'s revenue for the last quarter?

Oppenheimer Holdings Inc revenue for the last quarter amounts to 466.43M USD, increased 26.91

What is Oppenheimer Holdings Inc (OPY)'s earnings per share (EPS) for the last quarter?

Oppenheimer Holdings Inc. EPS for the last quarter amounts to 6.48 USD, increased 589.36

How many employees does Oppenheimer Holdings Inc (OPY). have?

Oppenheimer Holdings Inc (OPY) has 2906 emplpoyees as of April 06 2026.

What is Oppenheimer Holdings Inc (OPY) market cap?

Today OPY has the market capitalization of 973.82M USD.